Odanacatib [603139-19-1]
O1200
Estimated Purity≥99%
Product group Chemicals
Overview
- SupplierLKT Laboratories
- Product NameOdanacatib [603139-19-1]
- Delivery Days Customer7
- CertificationResearch Use Only
- Estimated Purity≥99%
- FormatDMSO 100 mg/mL (190.27 mM); Water Insoluble; Ethanol Insoluble
- Scientific DescriptionCathepsin K inhibitor.; MK0822; MK-0822
- Storage Instruction-20°C
- UNSPSC12352200
References
- Bone HG, Dempster DW, Eisman JA, et al. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int. 2015 Feb;26(2):699-712. PMID: 25432773. Hao L, Chen W, McConnell M, et al. A small molecule, Odanacatib, inhibits inflammation and bone loss caused by endodontic disease. Infect Immun. 2015 Jan 12. [Epub ahead of print]. PMID: 25583522. Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8. PMID: 18226527.